Key Highlights
- Shares reached a 52-week bottom at $60.54, marking approximately 35–36% decline from start of year
- Stifel reduced price objective from $90 down to $85 based on electrophysiology hospital purchasing trends before Q1 2026 results
- First quarter 2026 financial results scheduled for release on April 22, 2026
- Several Wall Street firms continue recommending Buy/Outperform positions while adjusting targets — RBC maintains $115 objective, UBS stands at $105
- InvestingPro identifies BSX among Most Undervalued securities with Fair Value assessment of $76.66
Boston Scientific has experienced significant headwinds throughout 2026. The medical device manufacturer saw shares reach a 52-week bottom of $60.54 on April 21, currently hovering between $60.43 and $60.99 — substantially below the 52-week peak of $109.50.
Boston Scientific Corporation, BSX
The decline represents approximately 36% from the beginning of the year, wiping out billions in value from the company’s $90.6 billion market capitalization.
Rick Wise, analyst at Stifel, revised his price objective on BSX downward to $85 from the previous $90 before the company releases first-quarter 2026 financial results on April 22, 2026. His Buy recommendation remains unchanged.
The adjustment stems from monthly electrophysiology (EP) hospital purchasing metrics that Stifel monitors to forecast quarterly performance ahead of official earnings announcements.
January figures showed approximately 92% reporting completion, February reached around 85%, while March data stood at roughly 60% — offering an incomplete yet informative view of EP revenue patterns.
According to this data, Stifel concludes that BSX’s Q1 US EP consensus revenue expectation of approximately $587 million falls “within the band of achievability.” The assessment suggests cautious optimism rather than alarm.
Stifel conducted comparative analysis with Johnson & Johnson and Abbott Laboratories, utilizing identical EP purchasing databases to validate projected versus reported revenues. The firm had previously identified potential downside exposure to US EP consensus revenues before the last quarter using comparable methodology.
Wall Street Price Objectives Remain Above Trading Levels
The steep share price decline hasn’t prompted widespread downgrades from the analyst community. Truist Securities maintained its Buy recommendation while trimming its target to $90 from $92. The firm anticipates cardiovascular segment expansion of 8.5% to 9% in the forthcoming report.
RBC Capital reaffirmed an Outperform stance with a $115 price objective following direct conversations with BSX management regarding expansion opportunities.
UBS preserved its Buy rating and $105 target after reviewing CHAMPION-AF trial outcomes for the Watchman cardiac implant. The study achieved all primary and secondary endpoints — a favorable result that UBS believes mitigates headline concerns.
However, complexity exists. The Watchman device demonstrated a marginally elevated ischemic stroke incidence when compared to non-vitamin K antagonist oral anticoagulants (NOACs), creating disappointment among certain investors.
Piper Sandler retained its Overweight classification after receiving input from a high-volume electrophysiologist who anticipates increased Watchman adoption regardless of the stroke findings.
Valuation Analysis Indicates Discount
InvestingPro has designated BSX among its most undervalued securities, establishing its Fair Value at $76.66 — approximately 27% above current trading levels.
Revenue expansion has stayed robust, with BSX delivering nearly 20% growth across the last twelve months. The fundamentals suggest operational strength rather than business deterioration — this appears to be equity market pressure.
Investor attention now shifts to April 22, when BSX unveils Q1 2026 financial results. That announcement will provide the initial concrete evidence of whether EP revenue performance aligned with Stifel’s data-driven projections.
